Last edition
News about "Novartis one year results of phase III MERLIN stud"
Novartis reported the first interpretable year one results of the phase III MERLIN study, a two-year study initiated in H2 2018, assessing the efficacy and safety of Beovu 6 mg versus aflibercept 2 mg given every four weeks following the loading phase in patients with wet age-related macular degeneration
Novartis One Year Results Of Phase III MERLIN Stud | 31/05/2021 | By Darshana | 170
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members